Interim report 1 january – 30 september 1999

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 1999

Proof of principle has been achieved in the development of new treatments for
obesity and high cholesterol. This triggers the first milestone payment in the
collaboration with Bristol-Myers Squibb.
Clinical indications have been prioritized in the Merck collaboration. The
project has been up-graded by Merck.
Patents on the estrogen receptor beta have been granted in Europe and in the
U.S.
Animal trials with new compound classes strengthen Karo Bio’s diabetes
project.
Net sales for the period amounted to SEK 46.0 million (46.6)
Net result after financial items for the period amounted to SEK -32.2 million
(-15.7).
Liquid funds and short-term investments as of 30 September amounted to SEK
182.3 million, compared with SEK 209.1 million as of 31 December 1998.

————————————————————
Please visit https://www.bit.se for further information
The following files are available for download:
https://www.bit.se/bitonline/1999/10/18/19991104BIT01000/bit0001.doc
https://www.bit.se/bitonline/1999/10/18/19991104BIT01000/bit0002.pdf
https://www.bit.se/bitonline/1999/10/18/19991104BIT01000/bit0003.xls Tabels